Supplementary information

Clinical information for patients analysed in the scope of this study. Three tables describe the clinical data of all patients analysed for NTN1/UNC5 expression (Supplementary Table 1a), EC treated in the Phase 1 clinical trial (Supplementary Table 1b) and the baseline characteristics of these patients (Supplementary Table 1c).Reporting Summary